Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...

Breast cancer patients who underwent postmastectomy breast reconstruction had lower sexual well-being scores compared with ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...

Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.

After a promising feasibility study showing the potential of its natural language processing models, MSK has ambitions to use them in patient care.

A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...